Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
October 04 2023 - 4:00AM
Myricx Bio (‘Myricx’), a UK biotech company focusing on the
discovery and development of a completely novel class of
selectively cytotoxic payloads for antibody-drug conjugates (ADCs),
today announces the appointment of Francesca Zammarchi, Ph.D., as
Chief Scientific Officer (CSO).
Dr. Zammarchi joins Myricx as it accelerates the development of
its pipeline of ADCs based on its first-in-class
N-myristoyltransferase inhibitor (NMTi) payload platform. She
brings over two decades of cancer biology research experience,
including developing ADCs, gained working in the biopharma industry
and in academia. At Myricx, as a senior member of the Leadership
Team, she will be responsible for the company’s internal and
partnered scientific programmes.
She joins Myricx from ADC Therapeutics SA (NYSE:
ADCT) where she served as Head of Preclinical Pharmacology.
During her 10 years at ADC Therapeutics, she worked as a cancer
biologist actively involved in the discovery and evaluation of new
projects for the company's portfolio, with responsibility for
preclinical pharmacology studies, and progressed multiple ADCs with
novel payloads through IND to BLA. Her earlier academic career
included Research Associate at Memorial Sloan-Kettering Cancer
Centre, and Research Associate and Visiting Fellow at Mount Sinai
School of Medicine. Dr. Zammarchi gained her Ph.D. in experimental
and molecular oncology and her B.Sc. in molecular biology from the
University of Pisa, Italy.
Welcoming Francesca to the company,
Myricx CEO Dr. Robin Carr said: “As we advance our unique
ADC pipeline against important cancer targets, Francesca’s
impressive background in ADC discovery and development provides an
ideal skillset to lead our programmes as CSO. We believe our
first-in-class selective cytotoxic payloads based on potent
inhibitors of N-myristoyltransferase (NMT) will provide important
advantages in the development of differentiated ADC
therapeutics.”
Dr. Francesca Zammarchi, CSO at Myricx, said:
“Having spent over a decade in R&D of novel ADC payloads, I am
impressed by Myricx’s preclinical data showing the potential of NMT
inhibitors to become the backbone of a new class of ADC drugs with
selective cancer cell killing activity. I look forward to working
with the Myricx team to expand and advance its ADC discovery
pipeline.”
Dr. Zammarchi will join the Myricx Bio team at its headquarters
in Kings Cross, London.
Notes to Editors:
About Myricx Bio - www.myricxbio.com
Myricx Bio (“Myricx”) is a UK biotech company focused on the
discovery and development of a completely novel class of selective
cytotoxic payloads for antibody-drug conjugates (ADCs), based on
inhibitors of N-myristoyltransferases (NMT) for the treatment of
cancer.
NMT is an enzyme that adds a specific lipid modification to a
number of protein targets key to cancer cell survival. Myricx is
advancing a pipeline of ADCs to address serious unmet needs in
oncology based on its NMT inhibitor (NMTi) payload chemistry
platform and has demonstrated excellent preclinical efficacy and
safety across multiple solid tumour-associated antigens and cancer
cell types.
Based in London, Myricx is a spin out from Imperial College
London and the Francis Crick Institute with investment from
Sofinnova Partners and Brandon Capital Partners.
Myricx Bio is the trading name of Myricx Pharma Limited.
Follow us on LinkedIn
For further information please contact:
At the CompanyDr. Robin Carr, CEO, Myricx Bio,
info@myricxbio.com
Media
Enquiries Sue Charles, Charles Consultants,
sue@charles-consultants.com, +44 (0)7986 726585
A photo accompanying this announcement is available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/75837e88-7904-406c-b002-6581fe96ad71
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2024 to May 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From May 2023 to May 2024